FDA Requests Updated Labeling for Testosterone Therapies

The US Food and Drug Administration (FDA) announced Thursday it is requesting updates to prescribing information for testosterone therapies, as reported by MT Newswires. The request aims to enhance the accuracy of safety and efficacy information for these drugs.

Details of the Action

The FDA did not provide specific details on the required labeling changes. However, the request covers all prescription testosterone therapies, including those produced by AbbVie (ABBV) such as AndroGel. Companies are expected to submit proposals within a specified timeframe.

Company Response

AbbVie (ABBV) has not issued an official statement in response to the FDA's request. The company manufactures AndroGel, one of the most popular topical testosterone treatments. It is expected to cooperate with the FDA to ensure compliance.

Precedents and Context

The FDA has previously issued warnings about the risks of testosterone therapies, including increased risk of heart attacks and strokes. In 2015, the FDA required labeling updates to include warnings about misuse. The new request is part of ongoing efforts to improve patient safety.

Potential Financial Impact

Updating labels may increase regulatory costs for AbbVie (ABBV) and other manufacturers. However, it is not expected to significantly impact AndroGel sales, which hold a large market share. Investors will monitor any changes in the company's future guidance.